Page 2,805«..1020..2,8042,8052,8062,807..2,8102,820..»

California's stem cell agency ponders a future without taxpayer support

Posted: March 19, 2012 at 6:55 pm

LOS ANGELES, Calif. - The creation of California's stem cell agency in 2004 was greeted by scientists and patients as a turning point in a field mired in debates about the destruction of embryos and hampered by federal research restrictions.

The taxpayer-funded institute wielded the extraordinary power to dole out $3 billion in bond proceeds to fund embryonic stem cell work with an eye toward treatments for a host of crippling diseases. Midway through its mission, with several high-tech labs constructed, but little to show on the medicine front beyond basic research, the California Institute for Regenerative Medicine faces an uncertain future.

Is it still relevant nearly eight years later? And will it still exist when the money dries up?

The answers could depend once again on voters and whether they're willing to extend the life of the agency.

Several camps that support stem cell research think taxpayers should not pay another cent given the state's budget woes.

"It would be so wrong to ask Californians to pony up more money," said Marcy Darnovsky of the Center for Genetics and Society, a pro-stem cell research group that opposed Proposition 71, the state ballot initiative that formed CIRM.

Last December, CIRM's former chairman, Robert Klein, who used his fortune and political connections to create Prop 71, floated the possibility of another referendum.

CIRM leaders have shelved the idea of going back to voters for now, but may consider it down the road. The institute recently submitted a transition plan to Gov. Jerry Brown and the Legislature that assumes it will no longer be taxpayer-supported after the bond money runs out. CIRM is exploring creating a non-profit version of itself and tapping other players to carry on its work.

"The goal is to keep the momentum going," board Chairman Jonathan Thomas said in an interview.

So far, CIRM has spent some $1.3 billion on infrastructure and research. At the current pace, it will earmark the last grants in 2016 or 2017. Since most are multi-year awards, it is expected to stay in business until 2021.

See the original post:
California's stem cell agency ponders a future without taxpayer support

Posted in Cell Medicine | Comments Off on California's stem cell agency ponders a future without taxpayer support

California's stem cell agency ponders its future

Posted: March 19, 2012 at 6:55 pm

LOS ANGELES (AP) The creation of California's stem cell agency in 2004 was greeted by scientists and patients as a turning point in a field mired in debates about the destruction of embryos and hampered by federal research restrictions.

The taxpayer-funded institute wielded the extraordinary power to dole out $3 billion in bond proceeds to fund embryonic stem cell work with an eye toward treatments for a host of crippling diseases. Midway through its mission, with several high-tech labs constructed, but little to show on the medicine front beyond basic research, the California Institute for Regenerative Medicine faces an uncertain future.

Is it still relevant nearly eight years later? And will it still exist when the money dries up?

The answers could depend once again on voters and whether they're willing to extend the life of the agency.

Several camps that support stem cell research think taxpayers should not pay another cent given the state's budget woes.

"It would be so wrong to ask Californians to pony up more money," said Marcy Darnovsky of the Center for Genetics and Society, a pro-stem cell research group that opposed Proposition 71, the state ballot initiative that formed CIRM.

Last December, CIRM's former chairman, Robert Klein, who used his fortune and political connections to create Prop 71, floated the possibility of another referendum.

CIRM leaders have shelved the idea of going back to voters for now, but may consider it down the road. The institute recently submitted a transition plan to Gov. Jerry Brown and the Legislature that assumes it will no longer be taxpayer-supported after the bond money runs out. CIRM is exploring creating a nonprofit version of itself and tapping other players to carry on its work.

"The goal is to keep the momentum going," board Chairman Jonathan Thomas said in an interview.

So far, CIRM has spent some $1.3 billion on infrastructure and research. At the current pace, it will earmark the last grants in 2016 or 2017. Since most are multi-year awards, it is expected to stay in business until 2021.

Read the original post:
California's stem cell agency ponders its future

Posted in Cell Medicine | Comments Off on California's stem cell agency ponders its future

Genetic research develops tools for studying diseases, improving regenerative treatment

Posted: March 19, 2012 at 6:55 pm

ScienceDaily (Mar. 19, 2012) Research from a Kansas State University professor may make it easier to recover after spinal cord injury or to study neurological disorders.

Mark Weiss, professor of anatomy and physiology, is researching genetic models for spinal cord injury or diseases such as Parkinson's disease. He is developing technology that can advance cellular therapy and regenerative medicine -- a type of research that can greatly improve animal and human health.

"We're trying to build tools, trying to build models that will have broad applications," Weiss said. "So if you're interested in neural differentiation or if you're interested in response after an injury, we're trying to come up with cell lines that will teach us, help us to solve a medical mystery."

Weiss' research team has perfected a technique to use stem cells to study targeted genetic modifications. They are among a handful of laboratories in the world using these types of models for disease. The research is an important step in the field of functional genomics, which focuses on understanding the functions and roles of these genes in disease.

The researchers are creating several tools to study functional genomics. One such tool involves developing new ways to use fluorescent transporters, which make it easier to study proteins and their functions. These fluorescent transporters can be especially helpful when studying neurological disorders such as Parkinson's disease, stroke and spinal cord injury.

"People who have spinal cord injury do not experience a lot of regeneration," Weiss said. "It is one of the problems of the nervous system -- it is not great at regenerating itself like other tissues."

The researchers want to discover a way to help this regenerative process kick in. By studying signals from fluorescing cells, they can understand how neural stem cells are reactivated.

"We want to try and make these genetic markers, and then we can test different kinds of treatment to see how they assist in the regenerative process," Weiss said.

Weiss' stem cell research has appeared in two recent journals: Stem Cells and Development and the Journal of Assisted Reproduction and Genetics. His research has been funded by the National Institutes of Health and university funds, including the Johnson Cancer Research Center.

Weiss' seven-member research team includes a visiting professor, two full-time researchers, a graduate student and three undergraduates. He has also been collaborating with researchers from the University of Kansas Medical Center.

Read this article:
Genetic research develops tools for studying diseases, improving regenerative treatment

Posted in Regenerative Medicine | Comments Off on Genetic research develops tools for studying diseases, improving regenerative treatment

Stem cell therapy banned in Kuwait

Posted: March 19, 2012 at 6:54 pm

(MENAFN - Arab Times) Ministry of Health (MoH) employees holding PhD degrees announced that they will participate in the sit-in demonstration carried out by the Labor Union of Health Ministry, reports Al-Seyassah daily.

In the press release, they said they are protesting against the fact that they are receiving the same salary scale and benefits as any other ministry employee with lower qualifications and if necessary, they are ready to even burn their PhD certificates at the sit-in to get the benefits they deserve according to their qualifications.

The sit-in will be carried out in front of Health Ministry headquarters in Sulaibikhat at 10 am on Tuesday, March 20, 2012.

The number of PhD holders has exceeded 100 considering the participation of PhD holders from other ministries as well.

Meanwhile, the MoH has banned stem cell therapy in the country until the committee tasked to set the standards for the treatment completes its work, reports Al-Anba daily quoting Director of Health License Department Dr Marzouq Al-Bader.

Al-Bader disclosed the ministry had earlier formed the committee to ensure the stem cell procedures are carried out in an appropriate manner to protect the patients. He added the ministry will also issue a decision soon to regulate the use of antibiotics in the private health sector.

Meanwhile, Al-Bader confirmed the ministry has endorsed around 51,000 female doctors in private hospitals and health centers. He said the ministry closely monitors the performance of female doctors and those found to have violated the law will be referred to the Medical Council for the necessary action.

On the issuance of licenses through the Internet, Al-Bader revealed his department has asked the ministry to activate the e-link system for this purpose.

He said the ministry has asked the Kuwait Municipality to issue permit for the construction of a building fit for the department's operations.

Meanwhile, the Medical Emergency Department at the Ministry of Health has affirmed its readiness to deal with emergency cases that may arise due to a series of dust storms engulfing the country.

Continued here:
Stem cell therapy banned in Kuwait

Posted in Stem Cell Therapy | Comments Off on Stem cell therapy banned in Kuwait

Human stem cell injections ease Parkinson's symptoms in monkeys

Posted: March 19, 2012 at 3:59 pm

London, March 19 (ANI): An injection of human embryonic stem cells (hESCs) into their brain helped monkeys with Parkinson's disease-like symptoms ease their suffering, say Japanese scientists.

These cells were injected into monkeys whose brains had been damaged by a chemical that destroys dopamine-producing neurons and so causes Parkinson's symptoms.

In the study conducted by Jun Takahashi of Kyoto University in Japan and colleagues, two monkeys received hESCs that had been matured into an early form of neural cell.

Six months later, the monkeys had recovered 20 to 45 per cent of the movement they had lost before treatment.

Post-mortems a year after treatment showed that the cells had developed into fully functioning dopamine-secreting neurons.

Another monkey that received less-mature neural cells also showed improvements.

"Monkeys starting with tremors and rigidity [began] to move smoothly, and animals originally confined to sitting down were able to walk around," New Scientists quoted Takahashi as saying.

But it will probably be four to six years before clinical trials in humans begin, according to the team. (ANI)

See the original post:
Human stem cell injections ease Parkinson's symptoms in monkeys

Posted in Stem Cell Videos | Comments Off on Human stem cell injections ease Parkinson's symptoms in monkeys

Physicians grow retinas from human blood-derived stem cells

Posted: March 19, 2012 at 3:59 pm

Among the primary causes of adult-onset blindness are degenerative diseases of the retina, such as macular degeneration and retinitis pigmentosa. While some treatments have been developed that slow down the rate of degeneration, the clinical situation is still generally unsatisfactory. But if you could grow a new retina, transplant might be a possible cure. Now new hope is springing up from a research project at the University of Wisconsin-Madison in which scientists have succeeded in growing human retinal tissue from stem cells.

Pluripotent stem cells are capable of forming nearly any tissue in the body including retinal tissue. There has been great controversy about using pluripotent stem cells for human research or treatment, as historically the only source was to harvest them from early stage human embryos. Instead, for this work the researchers were able to regress mature body cells back into the pluripotent stem cells from which they originally grew. The process is called reprogramming, and is accomplished by inserting a set of proteins into the cell.

To produce the pluripotent stem cells, a white blood cell was taken from a simple blood sample. Genes which code for the reprogramming proteins are inserted into a plasmid, a nonliving ring of DNA. The cell is then infected with the plasmid, rather as a virus infects a cell, with the difference that the plasmid's genes do not become part of the cell's genetic structure. As the reprogramming proteins are formed within the cell by the plasmid DNA, the cell has a good chance of being reprogrammed into a pluripotent stem cell. This stem cell can then be encouraged to grow and differentiate into retinal tissue rather than make more blood cells.

Laboratory-grown human retinal tissue will certainly be used in testing drugs and to study degenerative diseases of the retina, and may eventually make available a new transplantable retina, or a new retina that is grown in place within the eye.

The figure above compares a schematic of the human retina with a photomicrograph of laboratory-grown retinal tissue. The new tissue has separated into at least three layers of cells, with rudimentary photosensitive rods or cones (red) at the top of the picture, and nerve ganglia (blue-green) at the bottom. The blue cells in the middle layer are likely bipolar retinal cells. The structure of the lab-grown retinal tissue is similar to that of a normal human eye, as can be seen by comparison with the retina schematic. The cells also formed synapses, which provide the channels through which optical information flows to the brain.

"We don't know how far this technology will take us, but the fact that we are able to grow a rudimentary retina structure from a patient's blood cells is encouraging, not only because it confirms our earlier work using human skin cells, but also because blood as a starting source is convenient to obtain," says Dr. David Gamm, pediatric ophthalmologist and senior author of the study. "This is a solid step forward." Further steps are eagerly awaited by those living in the dark.

Source: University of Wisconsin School of Medicine and Public Health

See original here:
Physicians grow retinas from human blood-derived stem cells

Posted in Stem Cell Videos | Comments Off on Physicians grow retinas from human blood-derived stem cells

Breakthrough Beauty Procedure Using Your Own Stem Cells Offered in the Inland Empire

Posted: March 19, 2012 at 3:59 pm

UPLAND, CA (PRWEB) March 19, 2012

Imagine a procedure using a little of your own excess tummy fat as an injectable for the aging areas of the face, and then adding your own extra stem cells and blood to give it a good chance of surviving and growing. The Stem Cell Facelift with PRP (Platelet Rich Plasma) Therapy is now available at Allure Image Enhancement, making it one of the first medical practices in the Inland Empire to offer this breakthrough procedure.

Stem Cell Facelift with PRP Therapy provides an amazing full facial restoration and can simulate the effects of a face lift, brow lift, and total facial rejuvenation in one sitting. In addition, the benefits of the PRP Therapy with growth factors enhance stem cell survival, giving long lasting and potentially permanent results, says John Grasso MD, Medical Director at Allure Image Enhancement. I find these procedures to be an exciting new approach to the world of dermal fillers. Rather than using lab derived products, patients can enjoy the benefits of volume and longevity from their own cells.

Stem Cells often thought of as controversial and futuristic, are the latest beauty secret now available. Although injectable wrinkle treatments are very popular, there are many who shy away from putting anything foreign into their face. The two most common requests my patients ask me when it comes to anti-aging rejuvenation are: 1. Is there something natural I can use? and 2. Is there anything that lasts longer? Autologous fat transfer enhanced with stem cells and platelet rich plasma is going to change the world of Anti-Aging skin care, says Mina Grasso NP, owner of Allure Image Enhancement. For those who do not have adequate fat deposits or choose not to have autologous fat transfer can still benefit from the healing and repair response of various growth factors and cytokines with PRP alone or combined with manufactured fillers.

Fat transfer has been around for many years and may yield inconsistent results: 50% of the transferred fat usually breaks down within 2 years. Fat is an abundant source of mesenchymal stem cells. The difficulty is that in obtaining fat using Liposuction, up to half of the natural stem cells may be damaged. By adding additional autologous stem cells to the suctioned fat, it closer approximates the original concentration of stem cells in fat in the body and may aid the transplanted fat cells in surviving longer. Platelet Rich Plasma (PRP), which contains growth factors and cytokines, stimulates a repair response in soft tissue when added to the stem cell enhanced fat cells. The grafted fat and stem cells as well as surrounding local cells are activated by these growth factors to generate new growth that plumps up sagging areas. The growth factors enhance the quality of skin on the surface and repair sun damage and skin color irregularities.

Using this revolutionary new method, stem cells show promise in regenerating collagenproducing fibroblasts, cartilage, muscle and even bone cells. Research trials are under way using stem cells to repair other damaged tissue such as lungs, knees, and hearts and reverse neurological degenerative diseases. Stem Cell Facelift with PRP results in long-lasting volume in the treated area, and patients can start to see improvement in skin texture a healthy glow as soon as three weeks following treatment, with dramatic results occurring over a period of two to four months and lasting for years..

About Allure Image Enhancement, Inc. Founded by Mina Grasso, RN, MSN, FNP-C, and her husband John Grasso MD. Allure Image Enhancement, Inc., for 15 years has served the Inland Empire with the latest in medical esthetics, providing services such as Botox Cosmetic, Restylane, Dysport, Juvderm, Latisse, Laser Hair Removal, Tattoo Removal, Laser Skin Rejuvenation, Vein Treatment, Body Shaping, and many more services.

Contact: Nicholas Rodgers, CAC Manager Allure Image Enhancement, Inc. 1113 Alta Ave., Suite 210 Upland, CA 91786 (909) 982-1074 nick(at)allureimage(dot)com http://www.allureimage.com

# # #

The rest is here:
Breakthrough Beauty Procedure Using Your Own Stem Cells Offered in the Inland Empire

Posted in Stem Cell Videos | Comments Off on Breakthrough Beauty Procedure Using Your Own Stem Cells Offered in the Inland Empire

Biostem U.S., Corporation Continues Building Its Scientific and Medical Board of Advisors With Appointment of Leading …

Posted: March 19, 2012 at 3:59 pm

CLEARWATER, FL--(Marketwire -03/19/12)- Biostem U.S., Corporation (OTCQB: BOSM.PK - News) (Pinksheets: BOSM.PK - News) (Biostem, the Company), a fully reporting public company in the stem cell regenerative medicine sciences sector, announced today the addition of Perinatologist Sanford M. Lederman, MD to its Scientific and Medical Board of Advisors (SAMBA).

As Chairman of the Department of Obstetrics and Gynecology at New York Methodist Hospital in Brooklyn, Dr. Lederman is consistently recognized by New Yorker Magazine's list of "Top Doctors" in New York. A specialist in high-risk pregnancy issues, Dr. Lederman has authored a number of scientific papers and is a highly regarded public speaker. He adds a very important dimension to the Biostem Scientific and Medical Board of Advisors by bringing specialized knowledge regarding the potential use of stem cell applications for the health of women and children.

Biostem President Dwight Brunoehler said, "Dr. Lederman is one of the most highly respected Obstetric and Gynecological physicians in the country. Sandy and I have worked together very actively on stem cell projects for over 18 years, including setting up a cord blood stem cell national donation system where all expectant moms have a chance to donate their baby's cord blood to benefit others."

Dr. Lederman stated, "Biostem's expansion plans mesh well with my personal interest in developing and advancing the use of non-controversial stem cells to improve the health of women and children. I have a particular interest in increasing the use of cord blood stem cells for in-utero transplant procedures, where stem cells are used to cure a potential life threatening disease such as sickle cell or thalassemia and other selective genetic disorders in a baby before it is even born."

Prior to accepting his current position with New York Methodist Hospital, Dr. Lederman was Residency Program Director and Vice Chairman of the Department of Obstetrics and gynecology at Long Island College Hospital in Brooklyn. At various times, he has served as a partner at Brooklyn Women's Health Care, President at Genetics East and Clinical Associate Professor at the State University of New York. He has served on the medical advisory board of several companies. He previously was Medical Director of Women's Health USA and was a founding member of the Roger Freeman Perinatal Society.

A graduate of Hunter College in New York, he received his initial medical training at Universidad Autonoma de Guadalajara School of Medicine. His initial internship was at New York Medical College in the Bronx. During the course of his career, Dr. Lederman has served and studied in various capacities at Long Island College Hospital in the Bronx, North Shore University Hospital in New York, Kings County Medical Center in Brooklyn, Long Beach Memorial Medical Center in California and the University of California at Irvine.

About Biostem U.S., CorporationBiostem U.S., Corporation (OTCQB: BOSM.PK - News) is a fully reporting Nevada corporation with offices in Clearwater, Florida. Biostem is a technology licensing company with proprietary technology centered around providing hair re-growth using human stem cells. The company also intends to train and license selected physicians to provide Regenerative Cellular Therapy treatments to assist the body's natural approach to healing tendons, ligaments, joints and muscle injuries by using the patient's own stem cells. Biostem U.S. is seeking to expand its operations worldwide through licensing of its proprietary technology and acquisition of existing stem cell related facilities. The company's goal is to operate in the international biotech market, focusing on the rapidly growing regenerative medicine field, using ethically sourced adult stem cells to improve the quality and longevity of life for all mankind.

More information on Biostem U.S., Corporation can be obtained through http://www.biostemus.com, or by calling Kerry D'Amato, Marketing Director at 727-446-5000.

Read the original post:
Biostem U.S., Corporation Continues Building Its Scientific and Medical Board of Advisors With Appointment of Leading ...

Posted in Stem Cell Treatments | Comments Off on Biostem U.S., Corporation Continues Building Its Scientific and Medical Board of Advisors With Appointment of Leading …

RBCC and n3D Aim to Help Bring Stem Cell Treatments to Market Faster

Posted: March 19, 2012 at 3:59 pm

NOKOMIS, Fla.--(BUSINESS WIRE)--

As global demand for innovative new stem-cell therapies grows by the day, Rainbow BioSciences (OTCBB:RBCC.OB - News) new agreement with n3D Biosciences could help to bring these therapies to market faster than ever before.

Stem cell therapies are becoming increasingly important to healthcare advancement around the world. Rising care delivery costs, worldwide population aging, and potential physician shortages are only three of the issues facing world healthcare providers. The cost to bring a new drug to market has soared to $1.3 billion, and there are now half as many drugs seeking approval as there were 15 years ago.

Rising costs and potential shortages have led to a boom in demand for stem cell therapies. These advanced treatments could soon help to ease costs and provide effective disease treatment, potentially improving patient outcomes and reducing health care costs. For that to happen, however, real challenges must be overcome. Translation of these therapies from the lab to the clinic is slow, and widespread implementation could be a decade away or more.

Thanks to n3Ds Bio-Assembler technology, however, the development timeline for many stem cell therapies could potentially be shortened significantly. The Bio-Assembler enables researchers to culture cells in three dimensions faster and more easily than ever before, streamlining testing and research.

On Thursday, RBCC announced the acquisition of an equity interest in n3D, a fully commercialized company with plans to sell the ground-breaking Bio-Assembler to labs and researchers all over the world. RBCC expects n3Ds value to grow considerably as word spreads about the game-changing technology.

For more information on Rainbow BioSciences, please visit http://www.rainbowbiosciences.com/investors.

Rainbow BioSciences will develop new medical and research technology innovations to compete alongside companies such as Celgene Corp. (NASDAQ:CELG),Cardinal Health, Inc.(NYSE:CAH), Abbott Laboratories (NYSE:ABT) andAffymax, Inc.(NASDAQ:AFFY).

Follow us on Twitter atwww.twitter.com/RBCCinfo.

About Rainbow BioSciences

Visit link:
RBCC and n3D Aim to Help Bring Stem Cell Treatments to Market Faster

Posted in Stem Cell Research | Comments Off on RBCC and n3D Aim to Help Bring Stem Cell Treatments to Market Faster

California's stem cell agency ponders a future without taxpayer support

Posted: March 19, 2012 at 3:58 pm

LOS ANGELES, Calif. - The creation of California's stem cell agency in 2004 was greeted by scientists and patients as a turning point in a field mired in debates about the destruction of embryos and hampered by federal research restrictions.

The taxpayer-funded institute wielded the extraordinary power to dole out $3 billion in bond proceeds to fund embryonic stem cell work with an eye toward treatments for a host of crippling diseases. Midway through its mission, with several high-tech labs constructed, but little to show on the medicine front beyond basic research, the California Institute for Regenerative Medicine faces an uncertain future.

Is it still relevant nearly eight years later? And will it still exist when the money dries up?

The answers could depend once again on voters and whether they're willing to extend the life of the agency.

Several camps that support stem cell research think taxpayers should not pay another cent given the state's budget woes.

"It would be so wrong to ask Californians to pony up more money," said Marcy Darnovsky of the Center for Genetics and Society, a pro-stem cell research group that opposed Proposition 71, the state ballot initiative that formed CIRM.

Last December, CIRM's former chairman, Robert Klein, who used his fortune and political connections to create Prop 71, floated the possibility of another referendum.

CIRM leaders have shelved the idea of going back to voters for now, but may consider it down the road. The institute recently submitted a transition plan to Gov. Jerry Brown and the Legislature that assumes it will no longer be taxpayer-supported after the bond money runs out. CIRM is exploring creating a non-profit version of itself and tapping other players to carry on its work.

"The goal is to keep the momentum going," board Chairman Jonathan Thomas said in an interview.

So far, CIRM has spent some $1.3 billion on infrastructure and research. At the current pace, it will earmark the last grants in 2016 or 2017. Since most are multi-year awards, it is expected to stay in business until 2021.

Original post:
California's stem cell agency ponders a future without taxpayer support

Posted in Stem Cell Research | Comments Off on California's stem cell agency ponders a future without taxpayer support

Page 2,805«..1020..2,8042,8052,8062,807..2,8102,820..»